Structure Therapeutics Inc. (NASDAQ:GPCR) Holdings Boosted by Bank of Montreal Can

Bank of Montreal Can grew its holdings in Structure Therapeutics Inc. (NASDAQ:GPCR) by 71.6% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 46,502 shares of the company’s stock after purchasing an additional 19,408 shares during the period. Bank of Montreal Can owned approximately 0.08% of Structure Therapeutics worth $1,941,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of GPCR. Principal Financial Group Inc. purchased a new stake in Structure Therapeutics in the 2nd quarter worth about $6,489,000. Natixis Advisors LLC boosted its holdings in shares of Structure Therapeutics by 29.4% during the second quarter. Natixis Advisors LLC now owns 19,005 shares of the company’s stock worth $746,000 after purchasing an additional 4,321 shares during the period. Gilbert & Cook Inc. purchased a new position in Structure Therapeutics during the second quarter valued at approximately $229,000. TD Asset Management Inc increased its stake in Structure Therapeutics by 47.9% in the 2nd quarter. TD Asset Management Inc now owns 211,590 shares of the company’s stock valued at $8,309,000 after buying an additional 68,490 shares during the period. Finally, Pier Capital LLC increased its stake in Structure Therapeutics by 3.7% in the 2nd quarter. Pier Capital LLC now owns 101,204 shares of the company’s stock valued at $3,974,000 after buying an additional 3,647 shares during the period. Institutional investors and hedge funds own 91.78% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently commented on GPCR. Morgan Stanley started coverage on shares of Structure Therapeutics in a report on Monday, September 23rd. They set an “overweight” rating and a $118.00 price target on the stock. JMP Securities cut their price target on Structure Therapeutics from $91.00 to $86.00 and set a “market outperform” rating for the company in a research note on Friday, August 9th. Cantor Fitzgerald reissued an “overweight” rating and issued a $65.00 price target on shares of Structure Therapeutics in a research note on Monday, September 23rd. Finally, HC Wainwright began coverage on shares of Structure Therapeutics in a research report on Wednesday. They set a “buy” rating and a $80.00 price objective on the stock. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Structure Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $85.67.

Structure Therapeutics Stock Performance

Shares of NASDAQ GPCR opened at $31.24 on Friday. The business’s 50-day simple moving average is $37.46 and its 200-day simple moving average is $39.32. Structure Therapeutics Inc. has a 52 week low of $26.61 and a 52 week high of $63.30. The firm has a market cap of $1.79 billion, a price-to-earnings ratio of -42.22 and a beta of -3.41.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.